Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity

Koch E, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, Haferkamp S, Kähler KC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pföhler C, Rahimi F, Schadendorf D, Schell B, Schlaak M, Terheyden P, Thoms KM, Schuler-Thurner B, Ugurel S, Ulrich J, Utikal J, Weichenthal M, Ziller F, Berking C, Heppt M (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Cancers MDPI

Book Volume: 14

Article Number: 518

Journal Issue: 3

DOI: 10.3390/cancers14030518

Abstract

Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.

Authors with CRIS profile

Elias Koch Department of Dermatology Anne Petzold Department of Dermatology Anja Wessely Department of Dermatology Beatrice Schuler-Thurner Medizinische Fakultät Carola Berking Lehrstuhl für Haut- und Geschlechtskrankheiten Markus Heppt Department of Dermatology

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Klinikum der Universität München DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Universitätsklinikum Mannheim DE Germany (DE) SRH Wald-Klinikum Gera DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Ruhr-Universität Bochum (RUB) DE Germany (DE) Harzklinikum Dorothea Christiane Erxleben DE Germany (DE) Universitätsklinikum des Saarlandes (UKS) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) DRK Krankenhaus Chemnitz-Rabenstein DE Germany (DE) Universitätsklinikum Köln DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Universitätsklinikum Regensburg DE Germany (DE) Universitätsklinikum Göttingen DE Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Universität zu Lübeck DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) Elbe Kliniken Stade-Buxtehude DE Germany (DE)

How to cite

APA:

Koch, E., Petzold, A., Wessely, A., Dippel, E., Gesierich, A., Gutzmer, R.,... Heppt, M. (2022). Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers, 14(3). https://doi.org/10.3390/cancers14030518

MLA:

Koch, Elias, et al. "Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity." Cancers 14.3 (2022).

BibTeX: Download